National registry data show 5-year overall survival in children and adolescents with cancer rose from 60% in 1975 to 90% in 2017.
|Poll|June 18, 2014
62-Year-Old Man Presents With Hematuria & Pain in the Right Flank
Author(s)Cesar A. Moran, MD
62-year-old man presents with hematuria and pain in the right flank. Further work-up reveals the presence of a right kidney mass and a left lower lobe lung mass. A kidney and lung biopsy are performed. What is your diagnosis?
Advertisement
62-year-old man presents with hematuria and pain in the right flank. Further work-up reveals the presence of a right kidney mass and a left lower lobe lung mass. A kidney and lung biopsy are performed and are shown below, respectively.
What is your diagnosis?
Advertisement
Related to this article
Model data suggest anthracycline-based chemotherapy may cost breast cancer survivors a median of 9.4 life-years through biological age acceleration.
Daniel Y.C. Heng, MD, MPH, FRCPC, discussed final LITESPARK-011 data, toxicity management, and treatment sequencing in advanced renal cell carcinoma.
In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.
NCCN guidelines now list the ArteraAI Prostate Test for risk stratification in patients with biochemical recurrence after radical prostatectomy.
In 60 patients undergoing gastrectomy, pre-consultation video aids shortened in-person consent visits and no patient had high decisional conflict.
The robotic endoscopy system obtained detrusor muscle in 94% of resected bladder lesions among the first 20 patients treated in the VIABLE study.
Neil Mehta, MD, and Laura Kulik, MD, discussed which patients with HCC awaiting liver transplant may benefit from bridging immunotherapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
Real-World Teclistamab Shows Deep Responses in R/R Multiple Myeloma Cohort
2
ArteraAI Prostate Test Added to NCCN Guidelines for BCR After Prostatectomy
3
Adding Pembrolizumab to SBRT Does Not Improve EFS in Early-Stage NSCLC
4
Virtuoso Robotic System Earns FDA De Novo Nod for En Bloc Bladder Resection
5